The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 354:1091-1093 March 9, 2006 Number 10
NextNext

Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
 by Galiè, N.
To the Editor: The Sildenafil Use in Pulmonary Hypertension (SUPER) trial (Nov. 17 issue)1 has led to the approval of sildenafil for the treatment of pulmonary arterial hypertension by the Food and Drug Administration and its European counterpart, the European Medicines Agency. Although the availability of a new treatment is embraced, the agencies have created a major problem by restricting the sildenafil dose to 20 mg three times a day. The SUPER trial involved three doses — 20 mg, 40 mg, and 80 mg three times a day. Although all doses had similar effects with regard to the distance walked . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.